ライフサイエンスコーパス: cardiovascular surgery

1 with severe heart or lung failure following cardiovascular surgery.

2 oreal membrane oxygenation therapy following cardiovascular surgery.

3 ndent risk factor for adverse outcomes after cardiovascular surgery.

4 transfusion strategy for patients undergoing cardiovascular surgery.

5 of neurologic injury, traumatic injury, and cardiovascular surgery.

6 nal fluid (CSF) of patients undergoing major cardiovascular surgery.

7 ve heart failure, myocardial infarction, and cardiovascular surgery.

8 Two patients had prior noncoarctation cardiovascular surgery.

9 sed extensively as a hemostatic agent during cardiovascular surgery.

10 an acute myocardial infarction or undergoing cardiovascular surgery.

11 prevention of atrial fibrillation following cardiovascular surgery.

12 on and the length of hospital stay following cardiovascular surgery.

13 istered to prevent thrombus formation during cardiovascular surgery.

14 with increased morbidity and mortality after cardiovascular surgery.

15 nt of a generalized inflammatory reaction to cardiovascular surgery.

16 n is associated with increased lactate after cardiovascular surgery.

17 nship with microcirculatory blood flow after cardiovascular surgery.

18 potent, rapid onset anticoagulant to support cardiovascular surgeries.

19 ness (22.1%) and patients who have undergone cardiovascular surgery (15.9%).

20 CP were diverse, the most common being prior cardiovascular surgery (25%).

21 Adult and pediatric cardiovascular surgery (29% [CI, 21% to 33%]), body and

22 use (36.5% versus 52.3%; P<0.001), and prior cardiovascular surgery (38.6% versus 50.7%; P<0.001).

23 ing was intensive care unit (487 [37.0%]) or cardiovascular surgery (434 [33.0%]).

24 Cardiovascular surgeries (53 023; 8%) alone accounted fo

25 In patients who underwent cardiovascular surgery, a correlation was noted between

26 oreal membrane oxygenation support following cardiovascular surgery and aimed to improve established

27 ts and renal function in patients undergoing cardiovascular surgery and DHCA.

28 ict advanced AKI or hospital mortality after cardiovascular surgery and improve in SOFA outcome asses

29 rbidities (chronic kidney disease, diabetes, cardiovascular surgery), and a propensity score for hype

30 rom 19.1% in neurosurgery, 18.9% in thoracic-cardiovascular surgery, and 15.3% in general surgery to

31 commonly used after cardiac catheterization, cardiovascular surgery, and exposure to intravenous cont

32 cant morbidity and mortality associated with cardiovascular surgery, and is the end result of multipl

33 of acute kidney injury (AKI), with AKI after cardiovascular surgeries being a prototype of prognosis

34 ischemic conditioning in patients undergoing cardiovascular surgery, both with neutral results in ter

35 onstrated that POAF occurred in 29.8% of all cardiovascular surgery cases.

36 From 25 August to 28 September 1994, 7 cardiovascular surgery (CVS) patients at a California ho

37 inithoracotomy, and laparotomy from a single cardiovascular surgery department in an academic medical

38 compared with those with type II, underwent cardiovascular surgery earlier (mean age, 16.9 years vs.

39 dings suggest that high lactate levels after cardiovascular surgery, even in the setting of normal he

40 ) in the PC4 clinical registry that included cardiovascular surgery from August 2014 to June 2018.

41 In the past years, advances in pediatric cardiovascular surgery have occurred in many areas with

42 h-volume and low-volume hospitals performing cardiovascular surgery have similar complication rates b

43 etic grafts and patches are commonly used in cardiovascular surgery, however neointimal hyperplasia r

44 Admission to cardiovascular surgery ICU and mixed medical/surgical IC

45 native anticoagulation is available, but for cardiovascular surgery, if the operation cannot be delay

46 rgical coronary revascularization, and other cardiovascular surgery in many, but not in all, studies.

47 iseases, cardiology, addiction medicine, and cardiovascular surgery in October 2021.

48 patients without thrombocytopenia undergoing cardiovascular surgery in the absence of major hemorrhag

49 orthopedic surgery, neurosurgery, radiology, cardiovascular surgery, obstetrics and gynecology, and g

50 This review summarizes current cardiovascular surgery outcomes as they pertain to women

51 or clinical outcomes in randomized trials of cardiovascular surgery patients.

52 ostatic therapy in clinical settings such as cardiovascular surgery, postpartum hemorrhage, and traum

53 In addition, cTnT levels before cardiovascular surgery predicted postoperative survival

54 m the MD Anderson Department of Thoracic and Cardiovascular Surgery's prospectively registered, insti

55 ibrillation (AF) is a common complication of cardiovascular surgery that is associated with a signifi

56 rdium (BP) is a vascular biomaterial used in cardiovascular surgery that is typically cross-linked fo

57 , important to the history of cardiology and cardiovascular surgery, that were published in volume 1

58 ied high-risk subgroups (patients undergoing cardiovascular surgery, those admitted to intensive care

59 ase, recent myocardial infarction, and prior cardiovascular surgery to be associated with need for po

60 perinflammatory conditions and 10 in complex cardiovascular surgery under cardiopulmonary bypass.

61 f MACE (myocardial infarction, stroke, major cardiovascular surgery, unstable angina) and all-cause m

62 ve surgery, ascending aortic surgery, or any cardiovascular surgery was required in 24+/-4%, 5+/-2%,

63 vels were elevated in children who completed cardiovascular surgery with an open chest compared with

64 mitochondrial respiration in patients after cardiovascular surgery with cardiopulmonary bypass.

65 Cardiovascular surgery with ischemic cardioplegic arrest